Literature DB >> 1901113

A usage evaluation of total parenteral nutrition in pediatric patients.

K MacFarlane1, L Bullock, J F Fitzgerald.   

Abstract

Records of 20 consecutive pediatric patients receiving total parenteral nutrition over a 1-month period were reviewed for appropriateness of nutritional assessment and management. Each patient was monitored until total parenteral nutrition was discontinued or for a maximum of 2 weeks. A total of 124 therapy days were reviewed. Results demonstrated that only 35% of these patients had a nutritional assessment performed prior to initiation of therapy, and only 65% had nutritional goals determined. Nutritional goals were defined as patient-specific goals for fluid volume (FV), calories, protein, and fat emulsion. Analysis of data demonstrated that goals for FV were met on 62% of therapy days. Of the days on which FV goals were met, goals for calories, protein, and fat emulsion were met on 54%, 59%, and 51% of therapy days, respectively. Baseline serum triglyceride levels were measured in one of 20 patients. Serial laboratory monitoring was adequate, with the exception of hepatic enzymes and serum triglycerides, which were measured in 14 and 9 patients, respectively. Recommendations for pediatric parenteral nutrition therapy are discussed, as well as methods to implement these recommendations.

Entities:  

Mesh:

Year:  1991        PMID: 1901113     DOI: 10.1177/014860719101500185

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  2 in total

1.  Utilization patterns of total parenteral nutrition in a university hospital. A methodological approach.

Authors:  E Frankfort; C Zimmerman; R Van Dalen; Y A Hekster
Journal:  Pharm World Sci       Date:  1993-04-23

2.  Evaluation of parenteral nutritional support in the surgical and medical wards of a referral teaching hospital.

Authors:  Samaneh Bairami; Sepideh Elyasi; Hossein Khalili; Saeed Reza Jamali-Moghadam
Journal:  Daru       Date:  2012-10-19       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.